R. Mark Adams - Mar 6, 2023 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Signature
/s/ R Mark Adams by Stacy L Taylor, Attorney-in-Fact
Stock symbol
ADPT
Transactions as of
Mar 6, 2023
Transactions value $
-$203,487
Form type
4
Date filed
3/8/2023, 07:03 PM
Previous filing
Jan 11, 2023
Next filing
Apr 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Award $0 +88.7K +78.1% $0.00 202K Mar 6, 2023 Direct
transaction ADPT Common Stock Sale -$56K -6.53K -3.23% $8.57 196K Mar 6, 2023 Direct F1
transaction ADPT Common Stock Sale -$148K -17.2K -8.77% $8.60 178K Mar 7, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (right to buy) Award $0 +133K $0.00 133K Mar 6, 2023 Common Stock 133K $8.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.
F3 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.245 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4 The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.